NCT07048652

Brief Summary

This will be a cross-sectional descriptive study aimed at evaluating the role of high-resolution computed tomography (HRCT) in diagnosing Idiopathic Pulmonary Fibrosis (IPF).

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
68

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 17, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 24, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 2, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2026

Completed
Last Updated

July 2, 2025

Status Verified

June 1, 2025

Enrollment Period

6 months

First QC Date

June 24, 2025

Last Update Submit

July 1, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • high-resolution computed tomography (HRCT)

    Idiopathic Pulmonary Fibrosis (IPF) high-resolution computed tomography (HRCT) scans are crucial for diagnosis and assessment of disease severity. HRCT findings typically show a reticular pattern with traction bronchiectasis and honeycombing, predominantly in the subpleural and basal regions of the lungs

    12 Months

Interventions

High-resolution computed tomography (HRCT) plays a crucial role in diagnosing and managing Idiopathic Pulmonary Fibrosis (IPF). It helps identify the characteristic pattern of IPF, known as Usual Interstitial Pneumonia (UIP), and can sometimes obviate the need for lung biopsy.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Idiopathic Pulmonary Fibrosis (IPF): IPF is defined as a chronic, progressive fibrotic interstitial lung disease diagnosed based on clinical evaluation, exclusion of other potential causes, and characteristic radiological findings on high-resolution CT (HRCT).

You may qualify if:

  • Patients aged 18 years and above.
  • Patients clinically suspected of having IPF.
  • Patients referred for HRCT examination.
  • Patients who provide informed consent to participate in the study.

You may not qualify if:

  • Patients with a known diagnosis of other interstitial lung diseases.
  • Patients with comorbid conditions that could mimic IPF.
  • Patients who are pregnant.
  • Patients with incomplete medical records or imaging studies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AYK Hospital

Lahore, Pakistan

Location

MeSH Terms

Conditions

Idiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Pulmonary FibrosisLung Diseases, InterstitialLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 24, 2025

First Posted

July 2, 2025

Study Start

March 17, 2025

Primary Completion

September 1, 2025

Study Completion

February 28, 2026

Last Updated

July 2, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations